We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

By LabMedica International staff writers
Posted on 03 Nov 2016
Print article
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).
An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins.

Asparagine (N)-linked glycosylation is a protein modification process that is critical for glycoprotein folding, stability, and cellular localization. To identify small molecules that would inhibit new targets in this biosynthetic pathway, investigators at Yale University (New Haven, CT, USA) and colleagues at several other institutions initiated a cell-based high-throughput screen and lead-compound-optimization campaign. During this campaign the researchers screened more than 350,000 chemical compounds while searching for those that could partially disrupt glycosylation. The result was the small molecule cell-permeable inhibitor NGI-1.

The investigators reported in the October 3, 2016, online edition of the journal Nature Chemical Biology that NGI-1 targeted oligosaccharyltransferase (OST), a hetero-oligomeric enzyme that exists in multiple isoforms and transfers oligosaccharides to recipient proteins.

In non-small-cell lung cancer (NSCLC) cells, NGI-1 blocked cell-surface localization and signaling of the epidermal growth factor receptor (EGFR) glycoprotein, but selectively arrested proliferation in only those cell lines that were dependent on EGFR (or fibroblast growth factor, FGFR) for survival. In these cell lines, OST inhibition caused cell-cycle arrest accompanied by cell morphology changes that were hallmarks of senescence.

“This is important to cancer research because what we are looking for are therapies that do not have a lot of effect on normal cells but do have a lot of effect on tumor cells, and this falls into that category,” said senior author Dr. Joseph Contessa, associate professor of therapeutic radiology and of pharmacology at Yale University. “We have therapies, and they are good therapies, but they are not enough. We need to take the next step.”

Related Links:
Yale University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.